Agios Pharmaceuticals, Inc. AGIO · Stock Open Agios Pharmaceuticals, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Agios Pharmaceuticals, Inc. Analysis (AGIO)
Is Agios Pharmaceuticals, Inc. a good investment? Agios Pharmaceuticals, Inc. (AGIO) is currently trading at 31.38 USD. Market analysts have a consensus price target of 45.88 USD. This suggests a potential upside from current levels.
Earnings Schedule: Agios Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -4.04.
Investor FAQ
Does Agios Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Agios Pharmaceuticals, Inc.?
Agios Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -7.01.
Company Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Community Discussion